Takeda Acquires Rights to Cx601, Possible Stem Cell Therapy for Perianal Fistulas in Crohn’s Patients
News
Takeda Pharmaceuticals has entered an exclusive licensing agreement with TiGenix to develop and commercialize Cx601 as a treatment for complex perianal fistulas in patients with Crohn’s disease. The agreement applies to Europe, ... Read more